ENDECE Neural

ENDECE Neural, a wholly-owned subsidiary of ENDECE, was founded in 2011 and focuses on developing the first drug capable of inducing remyelination in patients with damaged nerves. The company leverages decades of accumulated knowledge on how to activate estrogen receptors in specific ways to influence gene regulation.